^
Association details:
| Biomarker: | GRM1 overexpression |
|---|---|
| Cancer: | Liposarcoma |
| Drug: | Xpovio (selinexor) (XPO1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Molecular predictors of response to selinexor in advanced unresectable de-differentiated liposarcoma (DDLS).
Published date:
05/19/2021
Excerpt:
Expression of CALB1...was significantly lower in sensitive tumors (adjusted P [Padj] = 7.5x10-20), and expression of GRM1...was higher in selinexor sensitive tumors (Padj= 0.003). These findings were confirmed in an independent validation set (Padj = 0.01 – 0.02)....Selinexor sensitive DDLS tumors showed low expression of CALB1 and high GRM1.
DOI:
10.1200/JCO.2021.39.15_suppl.11509
Trial ID:
